communityacquir
pneumonia
cap
lead
caus
death
worldwid
despit
vast
divers
respiratori
microbiota
streptococcu
pneumonia
remain
preval
pathogen
among
etiolog
agent
despit
signific
decreas
mortal
rate
lower
respiratori
tract
infect
recent
decad
cap
rank
third
caus
death
brazil
sinc
latest
guidelin
cap
sociedad
brasileira
de
pneumologia
e
tisiologia
sbpt
brazilian
thorac
associ
publish
major
advanc
applic
imag
test
etiolog
investig
risk
stratif
admiss
prognost
score
stratif
use
biomark
recommend
antibiot
therapi
durat
prevent
vaccin
review
topic
sbpt
committe
respiratori
infect
summon
member
recogn
experi
cap
brazil
identifi
issu
relev
clinic
practic
requir
updat
given
public
new
epidemiolog
scientif
evid
twelv
topic
concern
diagnost
prognost
therapeut
prevent
issu
develop
topic
divid
among
author
conduct
nonsystemat
review
literatur
give
prioriti
major
public
specif
area
includ
origin
articl
review
articl
systemat
review
author
opportun
review
comment
question
produc
singl
final
document
approv
consensu
communityacquir
pneumonia
cap
lead
caus
death
worldwid
signific
impact
morbid
rate
despit
vast
divers
respiratori
microbiota
widespread
dissemin
potenti
pathogen
agent
phenomenon
global
occurr
viral
epidem
streptococcu
pneumonia
remain
preval
pathogen
among
etiolog
agent
cap
brazil
well
countri
signific
decreas
mortal
rate
respiratori
tract
infect
although
magnitud
decreas
lessen
recent
decad
among
pneumonia
cap
remain
one
greatest
impact
third
lead
caus
mortal
brazil
although
absolut
number
death
brazil
increas
popul
growth
age
mortal
rate
cap
standard
age
decreas
observ
improv
socioeconom
situat
greater
access
health
care
nation
avail
antibiot
vaccin
polici
partial
explain
decreas
mortal
rate
brazil
sinc
latest
guidelin
cap
sociedad
brasileira
de
pneumologia
e
tisiologia
sbpt
brazilian
thorac
associ
publish
sever
topic
review
advanc
applic
imag
test
advanc
impact
etiolog
investig
particularli
investig
viral
etiolog
atyp
pathogen
subgroup
patient
risk
stratif
admiss
prognost
score
stratif
role
biomark
therapeut
manag
recommend
antibiot
therapi
durat
recommend
regard
influenza
pneumococc
vaccin
author
consensu
determin
specif
topic
address
basi
relev
public
literatur
cap
regard
imag
test
etiolog
investig
risk
stratif
admiss
prognost
score
stratif
use
biomark
recommend
antibiot
therapi
durat
prevent
vaccin
review
topic
sbpt
committe
respiratori
infect
summon
member
recogn
experi
cap
brazil
develop
question
concern
previous
determin
topic
question
divid
among
author
conduct
nonsystemat
review
literatur
give
prioriti
major
public
specif
area
includ
origin
articl
review
articl
systemat
review
particip
opportun
review
comment
question
produc
document
approv
consensu
end
process
chest
xray
combin
anamnesi
physic
examin
part
classic
diagnost
triad
cap
recommend
avail
posteroanterior
later
chest
xray
routin
perform
addit
contribut
diagnosi
chest
xray
allow
us
assess
extent
lesion
detect
complic
well
facilit
differenti
diagnosi
despit
exist
numer
guidelin
consensu
regard
recommend
manag
cap
primari
care
especi
term
ancillari
test
often
readili
avail
level
care
clinician
sure
diagnosi
chest
xray
requir
treatment
initi
antimicrobi
prescrib
appropri
howev
fewer
physician
abl
diagnos
pneumonia
sole
basi
physic
examin
context
chest
xray
mandatori
patient
suspect
cap
chest
xray
also
recommend
doubt
diagnosi
differenti
diagnosi
lung
cancer
requir
treatment
followup
clinic
respons
unsatisfactori
chest
xray
recommend
patient
admit
hospit
chest
ultrasound
cu
greater
sensit
accuraci
detect
parenchym
chang
chest
xray
major
ultrasound
find
cap
includ
consolid
focal
interstiti
pattern
subpleur
lesion
pleural
line
abnorm
specif
cu
consolid
wherea
chest
xray
reach
sensit
type
chang
bedsid
ultrasound
perform
clinician
emerg
depart
sensit
neg
predict
valu
diagnosi
cap
compar
respect
chest
xray
specif
similar
diagnost
method
conduct
ultrasound
specialist
ultrasound
reach
sensit
specif
howev
yield
ultrasound
conduct
clinician
emerg
depart
yet
evalu
robust
evid
need
import
bear
mind
use
us
pregnant
women
bedridden
individu
xray
qualiti
lower
desir
addit
cu
high
yield
detect
complic
pleural
effus
well
permit
visual
locul
caviti
referr
aspir
pleural
effus
whether
locul
one
indic
cu
therefor
need
specif
train
ultrasound
unavail
method
primari
care
mani
health
care
facil
brazil
current
restrict
use
ultrasound
advanc
care
center
chest
ct
sensit
method
identifi
infecti
involv
lung
parenchyma
despit
high
cost
high
level
radiat
exposur
chest
ct
especi
use
case
accuraci
chest
xray
chest
us
low
obes
patient
immunosuppress
patient
individu
previou
abnorm
radiolog
find
addit
chest
ct
indic
suspect
fungal
infect
assist
exclus
diagnos
select
case
one
studi
use
chest
ct
patient
suspect
cap
emerg
depart
result
patient
altern
diagnos
find
pulmonari
thromboembol
neoplasia
diagnos
pulmonari
tuberculosi
recent
author
demonstr
use
chest
ct
increas
rate
diagnosi
patient
cap
normal
chest
xray
may
also
confirm
diseas
patient
opac
chest
xray
would
allow
discontinu
antibiot
signific
proport
case
high
radiat
exposur
ct
author
suggest
use
chest
us
intermedi
ancillari
test
use
ct
diagnosi
difficulttodiagnos
case
addit
import
chest
ct
assess
caprel
complic
lung
abscess
locul
pleural
effus
investig
reason
lack
clinic
respons
treatment
emphas
although
may
inadequ
respons
empir
treatment
etiolog
test
necessari
patient
nonsever
cap
receiv
outpati
treatment
therefor
recommend
etiolog
test
perform
patient
sever
cap
cap
unrespons
initi
empir
treatment
regimen
well
icu
patient
remain
valid
select
test
perform
one
take
account
patient
age
presenc
comorbid
diseas
sever
prior
antiinfect
therapi
develop
new
method
microbiolog
identif
gener
microbiolog
identif
cap
particular
increas
chanc
adequ
choos
spectrum
antibiot
use
treatment
pneumonia
note
radiolog
method
chest
us
microbiolog
method
name
multiplex
pcr
matrixassist
laser
desorpt
ionizationtim
flight
mass
spectrometri
promis
method
rapid
identif
pathogen
regard
microbiolog
studi
direct
examin
cultur
sputum
sampl
nasotrach
aspir
patient
expector
meet
sampl
qualiti
criteria
fewer
epitheli
cell
leukocyt
per
field
examin
addit
technic
norm
collect
transport
analysi
biolog
sampl
adher
observ
studi
hospit
patient
cap
good
qualiti
sputum
sampl
obtain
total
sampl
specif
much
higher
sensit
pneumonia
vs
similar
bacteri
agent
identifi
note
treatment
case
pathogen
identifi
similar
treatment
start
empir
molecular
test
shown
effect
detect
atyp
agent
film
array
respiratori
panel
rapid
hour
multiplex
molecular
test
detect
respiratori
pathogen
virus
three
bacteria
mycoplasma
pneumonia
chlamydophila
pneumonia
bordetella
pertussi
anoth
test
nxtag
respiratori
pathogen
panel
identifi
virus
pneumonia
c
pneumonia
current
recommend
use
molecular
test
includ
highli
accur
rapid
test
influenza
rapid
molecular
test
tuberculosi
feasibl
hour
rapid
test
respiratori
virus
caus
cap
lower
respiratori
tract
infect
rapid
test
detect
atyp
pathogen
pneumonia
c
pneumonia
legionella
sp
b
pertussi
patient
sever
cap
etiolog
investig
basic
test
avail
sputum
smear
microscopi
sputum
cultur
blood
cultur
urinari
antigen
test
pneumonia
legionella
sp
serolog
test
eventu
cultur
atyp
pathogen
select
case
appropri
clinic
context
special
cultur
galactomannan
test
fungi
well
latest
antigen
molecular
biolog
test
virus
atyp
pathogen
may
perform
indic
routin
manag
cap
patient
mechan
ventil
nonrespond
initi
empir
therapi
less
common
etiolog
agent
suspect
well
case
differenti
diagnosi
noninfecti
lung
diseas
tumor
vascul
interstiti
lung
diseas
requir
may
necessari
collect
sampl
invas
via
bronchoscopi
endotrach
aspir
bronchoalveolar
lavag
thoracentesi
case
ipsilater
pleural
effus
advent
use
molecular
test
clinic
practic
signal
virus
play
relev
role
possibl
etiolog
agent
cap
studi
includ
pcr
diagnost
tool
scope
detect
virus
approxim
one
third
cap
case
adult
influenza
commonli
isol
viru
addit
influenza
viral
agent
rhinoviru
respiratori
syncyti
viru
parainfluenza
viru
adenoviru
metapneumoviru
consid
possibl
etiolog
agent
cap
musher
et
al
evalu
patient
hospit
cap
order
identifi
etiolog
agent
fortyfour
virus
identifi
patient
rhinoviru
coronaviru
parainfluenza
respiratori
syncyti
viru
metapneumoviru
influenza
virus
pathogen
detect
patient
author
found
strong
evid
activ
virus
caus
agent
pneumonia
patient
howev
uncertainti
remain
true
role
virus
cap
difficulti
determin
whether
virus
act
copathogen
colon
one
exampl
studi
jartti
et
al
show
presenc
virus
nasopharyng
swab
approxim
healthi
adult
howev
isol
influenza
respiratori
syncyti
viru
metapneumoviru
rare
asymptomat
adult
anoth
possibl
activ
virus
cap
would
impair
defens
mechan
upper
airway
facilit
establish
anoth
microorgan
lower
airway
seem
role
rhinoviru
coronaviru
interact
virus
bacteria
seem
associ
sever
clinic
profil
cap
johansson
et
al
demonstr
viralbacteri
coinfect
occur
case
respons
sever
pneumonia
requir
longer
hospit
cap
caus
bacteri
agent
alon
evid
studi
support
ancillari
test
particularli
molecular
test
pcr
indic
diagnosi
virus
especi
case
sever
cap
patient
diagnosi
cap
alway
assess
diseas
sever
precaut
direct
posit
impact
mortal
current
avail
prognost
score
system
measur
sever
help
predict
prognosi
cap
inform
decis
regard
site
care
outpati
inpati
icu
need
etiolog
investig
choic
antibiot
rout
administr
valid
instrument
includ
pneumonia
sever
index
psi
mental
confus
urea
respiratori
rate
blood
pressur
age
year
measur
urea
american
thorac
societyinfecti
diseas
societi
america
at
idsa
guidelin
systol
blood
pressur
multilobar
involv
albumin
respiratori
rate
tachycardia
confus
oxygen
ph
smartcop
sever
communityacquir
pneumonia
scap
last
three
relat
sever
pneumonia
icu
admiss
import
stress
diseas
sever
determin
score
system
major
factor
decis
regard
hospit
admiss
howev
factor
possibl
use
oral
drug
comorbid
psychosoci
factor
socioeconom
characterist
indic
vulner
individu
taken
account
ideal
spo
alway
monitor
spo
valu
indic
hospit
admiss
psi
compris
item
includ
demograph
characterist
comorbid
abnorm
laboratori
test
result
abnorm
radiolog
find
physic
examin
find
psi
classifi
patient
five
categori
estim
mortal
suggest
site
care
chart
howev
psi
may
underestim
cap
sever
young
patient
without
concomit
diseas
score
system
give
much
weight
age
presenc
comorbid
anoth
neg
point
use
mani
variabl
make
calcul
complex
howev
calcul
facilit
use
calcul
avail
onlin
psipneumonia
patient
outcom
research
team
port
score
psi
cap
psi
calcul
acronym
variabl
assess
mental
confus
abbrevi
mental
test
score
urea
mgdl
respiratori
rate
breathsmin
blood
pressur
systol
mmhg
diastol
mmhg
age
year
figur
measur
urea
simplifi
version
use
set
laboratori
test
avail
primari
care
figur
major
limit
exclus
comorbid
may
increas
risk
complic
cap
alcohol
heart
liver
failur
neoplasia
result
neg
predict
valu
mortal
slightli
lower
psi
howev
qualifi
simplic
immedi
applic
eas
use
whether
hospit
set
elsewher
sever
criteria
propos
atsidsa
consensu
guidelin
simplifi
version
classifi
major
minor
chart
presenc
one
major
criteria
septic
shock
need
mechan
ventil
indic
icu
admiss
presenc
three
minor
criteria
also
indic
intens
care
criteria
howev
lend
assess
outpati
guidelin
recommend
use
psi
inform
decisionmak
outpati
tool
predict
occurr
sever
cap
develop
assess
outcom
gener
risk
death
icu
admiss
outcom
includ
addit
need
icu
admiss
develop
sever
sepsi
need
mechan
ventil
risk
treatment
failur
scap
outcom
specif
associ
need
use
invas
noninvas
mechan
ventilatori
support
use
vasopressor
circulatori
support
smartcop
outcom
consid
object
marker
cap
sever
given
heterogen
indic
protocol
icu
admiss
across
differ
institut
health
care
system
major
criteria
ph
point
systol
blood
pressur
mmhg
point
minor
criteria
rr
breathsmin
point
pao
fio
point
urea
mgdl
point
alter
level
conscious
point
age
year
point
radiolog
find
multilobar
bilater
infiltr
point
score
predict
increas
risk
use
mechan
ventil
need
vasoact
drug
smartcop
score
system
follow
systol
blood
pressur
mmhg
point
multilobar
involv
point
albumin
gdl
point
rr
breathsmin
point
hr
bpm
point
mental
confus
point
spo
pao
mmhg
point
ph
point
therefor
recommend
patient
cap
object
evalu
emerg
room
initi
diseas
sever
earli
identif
risk
develop
sever
outcom
need
icu
admiss
develop
sever
sepsi
need
invas
noninvas
ventilatori
support
need
inotrop
support
risk
treatment
failur
scap
smartcop
simplifi
version
atsisda
criteria
although
extern
valid
still
requir
absenc
sever
cap
socioeconom
indic
hospit
admiss
concomit
decompens
diseas
hypoxemia
oral
intak
medic
possibl
score
score
score
less
psi
attend
physician
consid
outpati
treatment
patient
cap
biomark
defin
measur
molecul
help
diagnos
estim
prognosi
patient
clinic
condit
sinc
cap
condit
intens
inflammatori
activ
sever
studi
evalu
variou
biomark
creactiv
protein
procalcitonin
proadrenomedullin
lactat
natriuret
atrial
peptid
ddimer
cortisol
etc
recent
year
creactiv
protein
procalcitonin
commonli
studi
procalcitonin
produc
larg
quantiti
parenchym
cell
respons
bacteri
toxin
proinflammatori
cytokin
product
minim
presenc
viral
infect
procalcitonin
level
increas
within
h
bacteri
stimul
rapidli
creactiv
protein
level
even
specif
bacteri
infect
given
creactiv
protein
level
increas
inflammatori
process
creactiv
protein
secret
hepat
cell
respons
increas
level
recogn
sourc
creactiv
protein
lymphocyt
monocyt
neuron
atherosclerot
plaqu
creactiv
protein
level
peak
approxim
h
injuri
stimulu
plasma
halflif
creactiv
protein
approxim
h
health
diseas
et
al
demonstr
signific
improv
diagnost
accuraci
combin
determin
procalcitonin
creactiv
protein
level
clinic
sign
symptom
patient
suspect
cap
treat
primari
care
emerg
set
biomark
outperform
increas
leukocyt
count
bodi
temperatur
help
differenti
patient
bacteria
without
area
curv
clinic
sign
symptom
alon
ci
wherea
clinic
sign
symptom
combin
procalcitonin
ultrasensit
creactiv
protein
level
ci
p
need
mechan
ventil
recent
studi
investig
valu
four
biomark
three
sever
scale
predict
mortal
patient
cap
treat
emerg
set
result
show
procalcitonin
best
singl
biomark
predict
mortal
model
combin
procalcitonin
andor
creactiv
protein
psi
show
better
result
psi
alon
recent
studi
demonstr
procalcitonin
level
decreas
within
day
treatment
remain
mgl
risk
mortal
increas
studi
patient
cap
admit
icu
show
mortal
among
procalcitonin
level
decreas
rapidli
n
among
procalcitonin
level
decreas
slowli
n
among
procalcitonin
level
decreas
n
therefor
basi
find
studi
procalcitonin
use
aid
diagnosi
cap
procalcitonin
creactiv
protein
use
assess
treatment
respons
import
emphas
biomark
use
complement
clinic
evalu
rather
singl
criterion
determin
chang
therapeut
approach
chart
figur
recent
updat
metaanalysi
clinic
trial
includ
data
countri
demonstr
use
procalcitonin
guid
initi
durat
antibiot
therapi
result
reduc
risk
mortal
reduc
antibiot
use
reduc
risk
antibioticrel
side
effect
result
similar
type
lower
respiratori
tract
infect
import
emphas
treatment
failur
similar
case
antibiot
discontinu
guid
decreas
procalcitonin
level
case
procalcitonin
use
guid
antibiot
discontinu
initi
antibiot
regimen
determin
empir
imposs
obtain
microbiolog
result
would
enabl
choic
antibiot
direct
specif
agent
immedi
diagnosi
cap
choic
antibiot
take
follow
account
like
pathogen
site
diseas
acquisit
individu
risk
factor
presenc
concomit
diseas
epidemiolog
factor
recent
trip
allergi
costeffect
ratio
antibiot
coverag
atyp
pathogen
case
less
sever
cap
remain
controversi
sever
studi
shown
advantag
use
approach
crossov
studi
compar
vs
plu
macrolid
vs
new
fluoroquinolon
respiratori
pathogen
levofloxacin
moxifloxacin
gemifloxacin
demonstr
alon
inferior
antibiot
regimen
nonsever
cap
term
mortal
american
european
british
latinamerican
guidelin
differ
regard
treatment
outpati
british
european
guidelin
well
guidelin
latinoamericana
del
place
less
import
atyp
pathogen
less
sever
case
recommend
initi
coverag
pathogen
british
european
guidelin
recommend
amoxicillin
treatment
choic
reserv
macrolid
altern
atsidsa
guidelin
advoc
treatment
atyp
pathogen
pneumococci
suggest
macrolid
doxycyclin
antibiot
resist
chart
advantag
disadvantag
use
biomark
infecti
diseas
provid
inform
specif
infect
requir
antibiot
high
level
bacteri
infect
low
level
viral
infect
level
increas
rapidli
bacteri
infect
respons
depend
organ
level
may
alter
diseas
onset
clinic
radiolog
abnorm
may
help
defin
prognosi
improv
yield
sever
score
help
monitor
therapeut
respons
may
specif
clinic
manifest
may
help
reduc
antibiot
use
without
advers
consequ
disadvantag
result
may
conflict
care
clinic
assess
previou
use
antibiot
may
rapidli
reduc
level
lead
falseneg
find
may
differenti
pneumonia
caus
atyp
pathogen
viral
pneumonia
alway
recogn
influenza
complic
bacteri
infect
distinguish
chemic
aspir
pneumonia
secondari
bacteri
aspir
pneumonia
adapt
et
al
suspect
retrospect
cohort
studi
outpati
cap
receiv
monotherapi
conduct
show
patient
requir
addit
treatment
occur
older
patient
women
patient
comorbid
drug
associ
treatment
failur
follow
macrolid
tetracyclin
new
fluoroquinolon
brazil
recent
data
indic
pneumococc
resist
penicillin
concern
less
sever
case
cap
propos
execut
group
respons
present
recommend
use
monotherapi
macrolid
outpati
comorbid
recent
use
antibiot
risk
factor
resist
contraind
histori
allergi
drug
chart
case
suggest
fluoroquinolon
use
avoid
recent
warn
us
food
drug
administr
regard
potenti
risk
sever
side
effect
fluoroquinolon
reserv
patient
risk
factor
sever
diseas
treatment
option
situat
benefit
would
outweigh
potenti
risk
regard
macrolid
azithromycin
effect
vitro
strain
haemophilu
influenza
clarithromycin
therefor
prefer
patient
copd
risk
infect
resist
pathogen
risk
treatment
failur
higher
patient
use
antibiot
within
previou
three
month
patient
come
region
local
rate
resist
macrolid
greater
occur
instanc
unit
state
countriesand
patient
concomit
diseas
copd
liver
kidney
diseas
cancer
diabet
congest
heart
failur
alcohol
immunosuppress
specif
case
combin
therapi
macrolid
monotherapi
respiratori
fluoroquinolon
least
day
recommend
outpati
treatment
cap
monotherapi
respiratori
fluoroquinolon
levofloxacin
moxifloxacin
gemifloxacin
combin
therapi
macrolid
guidelin
recommend
treatment
ward
patient
cap
regimen
provid
good
coverag
produc
good
result
infect
caus
pneumonia
pneumonia
c
pneumonia
h
influenza
legionella
sp
respiratori
fluoroquinolon
provid
wide
microbiolog
coverag
conveni
dose
schedul
abil
switch
parenter
oral
therapi
howev
excess
use
respiratori
fluoroquinolon
induc
subsequ
emerg
multidrugresist
organ
among
treat
patient
also
observ
note
ciprofloxacin
despit
secondgener
fluoroquinolon
recommend
treatment
cap
caus
commun
pathogen
lack
activ
pneumococcu
gramposit
organ
monotherapi
macrolid
indic
brazil
use
case
high
preval
pneumonia
resist
class
antibiot
accord
data
survey
age
group
pneumococc
resist
erythromycin
found
total
sampl
sensit
strain
found
among
patient
year
age
resist
found
total
sampl
total
sampl
includ
age
group
month
year
age
rate
pneumonia
resist
erythromycin
actual
need
specif
coverag
atyp
pathogen
debat
current
literatur
studi
investig
issu
demonstr
incid
legionella
sp
low
nonsever
cap
monotherapi
inferior
combin
therapi
macrolid
monotherapi
fluoroquinolon
result
investig
dose
adjust
occur
legionella
sp
found
studi
compar
combin
therapi
macrolid
monotherapi
fluoroquinolon
shown
differ
mortal
length
hospit
stay
prescript
oral
antibiot
current
recommend
use
plu
macrolid
respiratori
fluoroquinolon
alon
alon
use
legionella
sp
posit
exclud
chart
sever
cap
studi
evalu
combin
therapi
shown
favor
result
regard
variou
clinic
outcom
larg
observ
studi
patient
sever
cap
n
compar
monotherapi
combin
therapi
two
antibiot
term
earli
mortal
day
multivari
analysi
mortal
significantli
differ
dual
therapi
monotherapi
hazard
ratio
hr
ci
p
contrast
combin
chart
empir
antibiot
therapi
communityacquir
pneumonia
comorbid
recent
use
antibiot
risk
factor
resist
contraind
histori
allergi
drug
amoxicillin
amoxicillin
clavulan
acid
macrolid
azithromycin
clarithromycin
risk
factor
sever
diseas
recent
use
antibiot
macrolid
allerg
moxifloxacin
levofloxacin
gemifloxacin
treatment
ward
patient
thirdgener
cephalosporin
ceftriaxon
cefotaxim
amoxicillin
clavulan
acid
macrolid
azithromycin
clarithromycin
thirdgener
cephalosporin
ceftriaxon
cefotaxim
amoxicillin
clavulan
acid
macrolid
azithromycin
levofloxacin
moxifloxacin
gemifloxacin
monotherapi
treatment
icu
patient
thirdgener
cephalosporin
ceftriaxon
cefotaxim
ampicillinsulbactam
macrolid
azithromycin
clarithromycin
thirdgener
cephalosporin
ceftriaxon
cefotaxim
respiratori
quinolon
targetspecif
therapi
penicillinresist
pneumococcu
sever
highdos
amoxicillin
gday
amoxicillin
clavulan
acid
gday
altern
ceftriaxon
cefotaxim
cefepim
ceftarolin
macrolid
respiratori
fluoroquinolon
sever
ceftriaxon
cefotaxim
cefepim
ceftarolin
methicillinresist
staphylococcu
aureu
communityacquir
clindamycin
linezolid
vancomycin
methicillinresist
aureu
linezolid
vancomycin
extendedspectrum
enterobacteriacea
ertapenem
pseudomona
spp
antipseudomon
fluoroquinolon
piperacillintazobactam
meropenem
polymyxin
b
monotherapi
combin
therapi
patient
suspect
aspir
pneumonia
aspir
pneumonia
quinolon
thirdgener
cephalosporin
aspir
gastric
content
necrot
pneumonia
lung
abscess
sever
periodont
diseas
inhibitor
piperacillintazobactam
clindamycin
moxifloxacin
therapi
increas
likelihood
adequ
initi
therapi
defin
one
antibiot
vitro
activ
microorgan
identifi
absenc
identif
treatment
start
icu
admiss
requir
adjust
h
later
adequ
initi
therapi
independ
associ
better
surviv
gener
cohort
hr
ci
p
observ
studi
compar
impact
mortal
combin
therapi
least
two
antimicrobi
differ
mechan
action
monotherapi
antimicrobi
combin
icu
patient
sever
sepsi
septic
shock
among
patient
communityacquir
infect
cap
mortal
rate
significantli
lower
patient
receiv
combin
therapi
differ
class
antibiot
receiv
monotherapi
antimicrobi
combin
vs
p
casecontrol
studi
chang
antibiot
therapi
prescript
administr
practic
favor
combin
therapi
macrolid
plu
time
earli
administr
associ
reduct
mortal
pneumococc
pneumonia
icu
patient
similar
result
observ
studi
use
similar
methodolog
involv
icu
patient
cap
caus
variou
etiolog
agent
exclud
pneumococci
prospect
observ
studi
includ
intub
patient
cap
septic
shock
sever
sepsi
found
severityadjust
statist
analysi
macrolid
use
associ
lower
icu
mortal
hr
ci
p
compar
fluoroquinolon
use
separ
analysi
patient
sever
sepsi
septic
shock
n
reveal
similar
result
hr
ci
p
systemat
review
metaanalysi
involv
almost
patient
sever
cap
macrolid
use
associ
rel
reduct
absolut
reduct
mortal
compar
nonmacrolid
therapi
dual
antibiot
therapi
macrolid
superior
combin
therapi
quinolon
systemat
review
metaanalysi
random
studi
need
confirm
result
high
risk
methodolog
bia
across
studi
analyz
therefor
combin
therapi
recommend
patient
sever
cap
indic
icu
admiss
reduc
mortal
antibiot
administ
earli
possibl
antibiot
regimen
prefer
includ
macrolid
administ
intraven
except
clinic
set
great
likelihood
specif
pathogen
causal
agent
see
antibiot
therapi
cap
recommend
use
monotherapi
combin
therapi
suggest
initi
antibiot
therapi
sever
cap
describ
chart
recognit
risk
factor
lead
etiolog
agent
cap
help
determin
optim
therapi
especi
age
dissemin
drugresist
bacteria
commun
current
classifi
bacteri
etiolog
agent
standard
pathogenss
pneumonia
h
influenza
aureu
pneumonia
group
streptococcu
sp
legionella
sp
chlamydophila
sp
moraxella
catarrhali
multidrugresist
pathogenscommunityacquir
methicillinresist
aureu
camrsa
penicillinresist
pneumococcu
pneumonia
caus
standard
pathogen
age
occup
exposur
presenc
comorbid
risk
factor
occur
invas
pneumococc
diseas
lung
common
patient
chronic
respiratori
diseas
diabet
heart
diseas
immunosuppress
pneumonia
caus
multidrugresist
pathogen
mainli
depend
local
epidemiolog
addit
rapidli
progress
necrot
pneumonia
typic
present
camrsa
associ
skin
lesion
group
sport
particip
healthi
individu
recent
new
group
multidrugresist
bacteria
associ
cap
patient
previou
contact
health
care
servic
home
care
servic
dialysi
servic
outpati
servic
chronic
wound
care
nurs
home
patient
mrsa
extendedspectrum
enterobacteriacea
multidrugresist
pseudomona
sp
common
agent
pneumonia
even
without
recent
hospit
simpli
patient
remain
colon
follow
risk
factor
infect
bacteria
hospit
within
day
episod
pneumonia
antibiot
use
within
previou
day
immunosuppress
use
gastric
acidsuppress
agent
enter
feed
hemodialysi
previou
intestin
colon
multidrugresist
bacteria
nasal
mrsa
unlik
firstlin
therapi
cap
base
region
factor
local
incid
standard
pathogen
patient
sever
factor
specif
target
therapi
risk
factor
local
preval
drugresist
microorgan
assess
view
guid
therapi
brazil
public
epidemiolog
multidrugresist
bacteria
respiratori
tract
data
region
report
reveal
mean
penicillin
sensit
respiratori
isol
observ
increas
circul
serotyp
adult
penicillin
sensit
report
describ
mean
ceftriaxon
sensit
mean
erythromycin
sensit
mean
trimethoprimsulfamethoxazol
sensit
mean
chloramphenicol
sensit
camrsa
nation
data
scarc
risk
factor
taken
account
occur
multidrugresist
pathogen
associ
health
care
servic
drug
choic
treatment
camrsa
infect
inhibit
toxin
product
clindamycin
linezolid
vancomycin
use
monotherapi
combin
therapi
linezolid
plu
clindamycin
vancomycin
plu
clindamycin
combin
therapi
rifampin
case
drugresist
strain
difficulti
penetr
necrot
tissu
penicillinresist
pneumococc
infect
treat
cephalosporin
includ
ceftriaxon
cefotaxim
cefepim
recent
studi
new
cephalosporin
ceftarolin
demonstr
superior
ceftriaxon
ceftriaxon
treatment
pneumococc
pneumonia
case
nonsever
infect
oral
monotherapi
choic
cefuroxim
ampicillinsulbactam
safe
option
region
low
resist
fluoroquinolon
sinc
pneumococci
rare
resist
case
camrsa
infect
object
suppress
toxin
product
treatment
choic
clindamycin
trimethoprim
sulfamethoxazol
linezolid
potenti
induc
clindamycin
resist
highinoculum
infect
via
efflux
ribosom
alter
taken
account
antibiot
disc
diffus
assay
dtest
identifi
induc
clindamycin
resist
erythromycinresist
clindamycinsuscept
aureu
isol
linezolid
shown
superior
vancomycin
treatment
sever
mrsa
infect
especi
icu
patient
infect
extendedspectrum
enterobacteriacea
treat
outpati
basi
ertapenem
dose
schedul
singl
intramuscular
intraven
daili
dose
allow
administ
dayhospit
basi
infect
drugresist
strain
pseudomona
sp
treat
fluoroquinolon
piperacillintazobactam
meropenem
polymyxin
b
monotherapi
combin
therapi
chart
optim
durat
antibiot
therapi
treatment
cap
yet
definit
establish
shortterm
antibiot
therapi
seem
appropri
given
provid
less
patient
exposur
effect
antibiot
reduc
occurr
advers
effect
reduc
develop
drug
resist
microorgan
improv
patient
adher
minim
length
hospit
stay
financi
cost
addit
longterm
treatment
favor
develop
bacteri
resist
occurr
potenti
sever
advers
effect
infect
clostridium
difficil
howev
shortterm
treatment
effect
longerterm
treatment
term
rate
mortal
complic
diseas
recurr
recommend
regard
optim
durat
antibiot
therapi
chang
time
discrep
issu
across
guidelin
tabl
treatment
durat
suffici
ensur
cap
treatment
success
consid
mortal
primari
outcom
also
consid
advers
effect
treatment
failur
may
vari
base
cap
sever
defin
current
avail
sever
score
treatment
last
day
seem
suffici
case
especi
nonsever
infect
accord
metaanalysi
evalu
efficaci
shortterm
less
day
regimen
adult
patient
mild
moder
cap
involv
patient
select
studi
shorterterm
treatment
underperform
rel
tradit
regimen
anoth
metaanalysi
investig
efficaci
safeti
shortterm
equal
less
day
treatment
vs
longterm
greater
equal
day
differ
treatment
cap
antibiot
dose
schedul
five
random
control
trial
involv
adult
patient
mild
moder
sever
includ
differ
found
shortterm
day
treatment
longterm
day
treatment
regard
clinic
success
n
patient
ci
microbiolog
improv
recurr
mortal
rate
advers
effect
document
uk
nation
institut
health
care
excel
publish
recommend
durat
treatment
determin
sever
pneumonia
rather
etiolog
agent
antibiot
chosen
therefor
mild
cap
monotherapi
day
seem
suffici
extend
treatment
consid
symptom
improv
day
moder
sever
cap
document
recommend
treatment
day
suffici
accord
work
group
consensu
opinion
given
avail
evid
come
analysi
subgroup
patient
one
studi
strategi
procedur
aim
shorten
durat
antibiot
therapi
test
compar
shortand
longterm
treatment
term
efficaci
murray
et
al
evalu
impact
multidisciplinari
intervent
intend
reduc
durat
antibiot
therapi
stop
date
antibiot
therapi
determin
basi
sever
diseas
assess
score
date
clinician
receiv
remind
clinic
pharmaci
depart
attend
physician
decid
basi
data
regard
patient
clinic
cours
whether
continu
treatment
intervent
result
reduct
durat
antibiot
therapi
reduct
rate
antibioticrel
advers
effect
reduct
mortal
length
hospit
stay
author
evalu
use
threestep
systemat
pathway
transit
intraven
oral
antibiot
therapi
therebi
reduc
length
hospit
stay
author
demonstr
use
object
criteria
switch
oral
antibiot
therapi
decid
hospit
discharg
result
reduct
length
hospit
stay
durat
intraven
antibiot
therapi
without
advers
consequ
addit
biomark
especi
creactiv
protein
procalcitonin
wide
studi
help
clinic
monitor
patient
cap
method
help
decid
whether
chang
discontinu
treatment
recommend
mild
cap
treat
outpati
basi
treatment
monotherapi
moder
sever
cap
treat
antibiot
regimen
discuss
period
day
treatment
extend
day
discret
attend
physician
infecti
cours
adequ
balanc
activ
immun
respons
control
inflamm
key
fight
infect
without
adjac
tissu
injuri
activ
hypothalamicpituitaryadren
axi
respons
product
cortisol
endogen
corticosteroid
pneumon
cours
induc
express
antiinflammatori
protein
inhibit
proinflammatori
molecul
recent
year
random
clinic
trial
metaanalys
evalu
role
corticosteroid
cap
publish
gap
still
fill
moderateto
highqual
evid
suggest
combin
antibiot
usual
therapi
corticosteroid
improv
cours
treat
patient
cap
benefit
includ
reduct
length
hospit
stay
time
clinic
stabil
well
reduct
rate
mechan
ventil
progress
acut
ard
studi
evalu
role
corticosteroid
sever
cap
requir
hospit
regard
mortal
role
corticosteroid
prevent
caprel
death
yet
well
defin
although
data
regard
individu
sever
present
suggest
benefit
therapi
subgroup
anoth
import
aspect
take
account
fact
treatment
regimen
use
clinic
trial
standard
tabl
show
main
corticosteroid
treatment
regimen
use
treatment
cap
two
import
random
clinic
trial
publish
blum
et
al
evalu
use
prednison
mgday
day
patient
patient
corticosteroidtr
group
shorter
time
clinic
stabil
control
group
day
vs
day
p
clinic
stabil
defin
return
normal
level
temperatur
hr
rr
spo
mental
statu
systol
blood
pressur
abil
toler
oral
food
intak
torr
et
al
test
effect
use
methylprednisolon
mgkg
everi
h
day
individu
sever
cap
defin
at
criteria
high
psi
risk
class
high
inflammatori
respons
character
serum
creactiv
protein
level
mgl
patient
receiv
methylprednisolon
lower
risk
treatment
failur
compar
control
group
ci
p
addit
studi
show
radiolog
cours
better
group
patient
receiv
methylprednisolon
distinguish
posit
aspect
studi
compar
previou
research
sampl
homogen
includ
phenotyp
individu
increas
inflammatori
express
high
creactiv
protein
level
regard
safeti
outcom
corticosteroid
use
result
good
toler
without
increas
incid
advers
effect
except
hyperglycemia
commonli
report
group
receiv
corticosteroid
therapi
howev
rate
complic
usual
attribut
corticosteroid
use
gastrointestin
bleed
neuropsychiatr
complic
hospit
readmiss
similar
corticosteroid
control
group
conclus
corticosteroid
use
sever
cap
prove
safe
benefici
sever
import
clinic
outcom
howev
studi
need
confirm
impact
corticosteroid
therapi
caprel
mortal
although
metaanalys
suggest
reduct
rate
especi
subgroup
patient
sever
present
hand
emphas
import
avoid
indiscrimin
use
corticosteroid
therapi
priorit
use
individu
like
benefit
clinic
higher
level
system
inflamm
context
creactiv
protein
consid
use
biomark
identifi
patient
higher
risk
caprel
complic
consequ
may
benefit
adjuv
corticosteroid
therapi
recommend
extrapol
patient
less
sever
cap
treat
outpati
basi
influenza
viral
infect
system
manifest
caus
virus
famili
orthomyxovirida
classifi
antigen
type
b
c
influenza
type
infect
associ
pandem
diseas
greater
sever
influenza
type
b
infect
associ
region
epidem
influenza
type
c
infect
associ
small
isol
outbreak
littl
clinic
relev
human
flu
caus
influenza
type
b
virus
associ
increas
morbid
mortal
patient
chronic
diseas
strong
relationship
influenza
infect
secondari
bacteri
pneumonia
follow
viral
infect
vaccin
reduc
intens
symptom
need
hospit
mortal
influenza
viru
high
mutat
rate
annual
season
epidem
due
new
subtyp
aris
small
antigen
drift
occur
viral
replic
occurr
mutat
viral
structur
contribut
increas
season
incid
diseas
justifi
need
annual
influenza
vaccin
given
vaccin
protect
temporari
composit
influenza
vaccin
determin
world
health
organ
basi
inform
referr
laboratori
regard
preval
circul
strain
world
health
organ
usual
make
annual
recommend
composit
vaccin
second
semest
next
year
vaccin
develop
cover
influenza
strain
like
circul
subsequ
year
brazil
avail
influenza
vaccin
made
inactiv
fragment
virus
therefor
carri
risk
infect
patient
obtain
cultur
deriv
embryon
chicken
egg
inactiv
vaccin
reduc
magnitud
respiratori
symptom
circul
viru
strain
similar
vaccin
strain
lead
greater
decreas
incid
diseas
two
type
influenza
vaccin
approv
brazilian
nation
health
oversight
agenc
use
countri
although
influenza
vaccin
use
age
month
onward
vaccin
priorit
highrisk
group
vaccin
schedul
brazilian
nation
ministri
health
prioriti
nonexclus
indic
peopl
histori
sever
allergi
chicken
egg
sign
anaphylaxi
receiv
vaccin
set
anaphylact
reaction
treat
remain
observ
least
minut
case
fever
vaccin
postpon
remiss
occur
case
histori
syndrom
occur
within
week
previou
dose
vaccin
care
medic
evalu
riskbenefit
ratio
recommend
administr
anoth
dose
except
aforement
case
precaut
need
vaccin
cold
compress
reliev
reaction
vaccin
inject
site
sever
case
medic
prescrib
pain
medic
use
sever
andor
unexpect
symptom
vaccin
report
facil
vaccin
perform
persist
symptom
advers
event
last
h
depend
symptom
investig
caus
two
type
pneumococc
vaccin
current
avail
pneumococc
polysaccharid
vaccin
conjug
carrier
protein
contain
capsular
polysaccharid
antigen
pneumococc
serotyp
pneumococc
conjug
vaccin
pcv
compos
capsular
polysaccharid
antigen
conjug
carrier
protein
latter
formul
increas
immunogen
stimul
immun
memori
cell
provid
longerlast
protect
two
new
conjug
vaccin
formul
contain
capsular
polysaccharid
antigen
pneumococc
serotyp
avail
brazil
approv
prevent
invas
pneumococc
diseas
children
age
year
younger
wherea
approv
children
age
week
older
adult
pneumococc
serotyp
associ
diseas
sever
therefor
clinic
impact
vaccin
depend
serotyp
coverag
administ
singl
dose
adult
age
year
older
includ
previous
vaccin
pneumococc
polysaccharid
vaccin
need
revaccin
subsequ
dose
establish
routin
sequenti
administr
recommend
brazilian
immun
societi
individu
age
year
older
individu
comorbid
sequenti
administr
recommend
dose
given
first
follow
dose
month
later
second
dose
year
first
one
peopl
receiv
dose
interv
recommend
given
year
second
dose
given
year
first
one
month
receiv
two
dose
recommend
dose
given
least
year
recent
dose
second
dose
given
age
year
recommend
third
dose
given
age
least
year
recent
dose
accord
vaccin
schedul
administ
adult
age
year
discret
attend
physician
pneumococc
polysaccharid
vaccin
result
reduct
occurr
invas
pneumococc
diseas
adult
popul
less
effect
prevent
cap
patient
reduc
immun
pneumococc
conjug
vaccin
result
reduct
case
vaccineserotyp
cap
reduct
case
bacteri
pneumonia
reduct
case
invas
pneumococc
diseas
vaccin
indic
individu
increas
risk
cap
indic
vaccin
adult
age
year
older
individu
year
age
chronic
heart
diseas
chronic
lung
diseas
sickl
cell
diseas
diabet
alcohol
liver
cirrhosi
cerebrospin
fluid
fistula
cochlear
implant
individu
year
age
immunosuppress
diseas
condit
hodgkin
diseas
lymphoma
leukemia
kidney
failur
multipl
myeloma
nephrot
syndrom
hiv
infect
aid
damag
spleen
spleen
organ
transplant
individu
year
age
receiv
immunosuppress
drug
longterm
corticosteroid
drug
use
treat
cancer
undergon
radiotherapi
adult
year
age
smoke
asthma
resid
nurs
home
longterm
care
facil
tabl
main
corticosteroid
treatment
regimen
use
treatment
communityacquir
pneumonia
treatment
regimen
torr
et
al
spain
methylprednisolon
mgkg
everi
h
day
fernandezserrano
et
al
spain
methylprednisolon
mg
everi
h
day
mg
everi
h
day
mgday
day
blum
et
al
switzerland
prednison
mgday
day
snijder
et
al
netherland
prednisolon
mgday
day
confalonieri
et
al
itali
hydrocortison
mgday
day
sabri
et
al
egypt
hydrocortison
mgday
day
li
et
al
china
methylprednisolon
mgday
day
